Chitogenx IncCanadian Securities Exchange:CHGXView on OTC Pink - Current Information
- LAST PRICE0.0050
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0050/ 248
- Ask / Lots0.0100/ 119
- Open / Previous Close--- / 0.0050
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Chitogenx Inc | 415.7K | -0.2x | --- |
Albert Labs International Corp | 372.1K | -0.1x | --- |
Many Bright Ideas Technologies Inc | 228.9K | -3.3x | --- |
Enlighta Inc | 256.2K | -1.1x | --- |
WPD Pharmaceuticals Inc | 579.9K | -4.0x | --- |
Mydecine Innovations Group Inc | 617.6K | 0.0x | --- |
Company Information
ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Contact Information
- Headquarters
- 16667 Hymus BlvdKIRKLAND, QC, Canada H9H 4R9
- Phone
- 514-782-0951
- Fax
- 514-782-8804
Executives
- Chairman of the Board, Interim Chief Executive Officer
- Pierre Laurin
- Chief Financial Officer, Senior Vice President
- Luc Mainville
- Senior Vice President - Medical Affairs
- Jonathan Sackier
- Director
- Steven Saviuk
- Independent Director
- Timothy Cunningham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $415.7K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 83.1M |
Chitogenx Inc does not pay a dividend. | |
Beta | -0.07 |
EPS | $-0.02 |
Book Value | $-0.07 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
